Voclosporin,a newly developed calcineurin inhibitor,received approval from the FDA on January 22,2021,for its use in treating adult lupus nephritis.Voclosporin is administered orally and exhibits minimal interindividual variability in its metabolic process,compared with other calmodulin phosphatase inhibitors,thus obviating the need for therapeutic monitoring.Voclosporin is predominantly metabolized by CYP3A4 and potential drug interactions should be considered when co-administering with other medications.In comparison to the placebo group,voclosporin treatment group demonstrated a higher proportion of patients achieving complete renal remission in a shorter duration.However,this drug may cause a decrease in estimated glomerular filtration rate and increase the risk of hypertension.Therefore,it is necessary to closely monitor patients'blood pressure and regularly assess renal function.This article provides a comprehensive review of the pharmacological effects,pharmacokinetics,clinical evaluation,safety,and dosage of voclosporin,to offer a reference for its rational clinical use.
NETL
NSTL
万方数据
